Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: A case series

Naoki Hayashi; Seigo Nakamura; Hiroshi Yagata; Yuji Shimoda; Hidekazu Ota; Gabriel N. Hortobagyi; Massimo Cristofanilli; Naoto T. Ueno

doi:10.1007/s10147-010-0173-3

Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: A case series

Naoki Hayashi, Seigo Nakamura, Hiroshi Yagata, Yuji Shimoda, Hidekazu Ota, Gabriel N. Hortobagyi, Massimo Cristofanilli, Naoto T. Ueno^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The human epidermal growth factor receptor 2 (HER2) gene is located on the long arm of chromosome 17 (Chr-17). While primary tumors with Chr-17 polysomy (polysomy 17) are histopathologically similar to HER2-negative tumors, the role of polysomy 17 in circulating tumor cells (CTCs) is still unknown. We report the detection rate of polysomy 17 in CTCs in patients with metastatic breast cancer (MBC). We determined the CTC count per 7.5 ml blood and polysomy 17 in CTCs at 3- to 4-week intervals up to 12 weeks in 52 patients. Polysomy was defined as Chr-17 ≥2.2. CTCs were detected in 40 of 52 patients (76.9%) during the study period, in 32 of the 52 patients (61.5%) at baseline, and in 21 of 49 patients (42.9%) at 3-4 weeks. Polysomy 17 in CTCs was present in 10 of 52 patients (19.2%) during the study period, in 5 of 52 patients (9.6%) at baseline, and in 7 of 49 patients (14.3%) at 3-4 weeks. The individual patient counts of polysomy 17 in CTCs/total count of CTCs examined for polysomy 17 at 3-4 weeks were 1/1, 1/7, 1/7, 2/27, 2/30, 2/50, and 3/50. Six of the 7 patients with polysomy 17 in CTCs had HER2-negative primary tumors. None of the CTCs displaying polysomy 17 themselves had HER2 amplification by FISH. In summary, polysomy 17 in CTCs was observed in only a small population of patients with MBC. We should prospectively evaluate its prognostic value in both HER2-positive and -negative metastatic breast cancer.

Original language	English (US)
Pages (from-to)	596-600
Number of pages	5
Journal	International Journal of Clinical Oncology
Volume	16
Issue number	5
DOIs	https://doi.org/10.1007/s10147-010-0173-3
State	Published - Oct 2011

Funding

The authors thank Bibari Nakamura, Keiko Shimizu, and all the staff from the Department of Breast Surgical Oncology, St. Luke’s International Hospital, for help in collecting clinical data; Masayuki Shimada, Takeshi Watanabe, and Yuki Matsuo from SRL Inc. for tissue analysis; and Sunita Patterson from the Department of Scientific Publications, MD Anderson Cancer Center, for editorial review. This research is supported in part by the National Institutes of Health through MD Anderson’s Cancer Center Support Grant, CA016672, and the Nellie B. Connally Breast Cancer Research Fund. G. N. Hortobagyi is a consultant to Merck, Novartis, and Sanofi-aventis, and received research funding from Novartis. Y. Shimada has employment with SRL Inc. The other authors have no conflict of interest.

Keywords

Breast neoplasm
Circulating tumor cell
HER2
Metastasis
Polysomy

ASJC Scopus subject areas

Hematology
Oncology
Surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10147-010-0173-3

Cite this

@article{877eb1e182c04f93b25d599d7d547e78,

title = "Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: A case series",

abstract = "The human epidermal growth factor receptor 2 (HER2) gene is located on the long arm of chromosome 17 (Chr-17). While primary tumors with Chr-17 polysomy (polysomy 17) are histopathologically similar to HER2-negative tumors, the role of polysomy 17 in circulating tumor cells (CTCs) is still unknown. We report the detection rate of polysomy 17 in CTCs in patients with metastatic breast cancer (MBC). We determined the CTC count per 7.5 ml blood and polysomy 17 in CTCs at 3- to 4-week intervals up to 12 weeks in 52 patients. Polysomy was defined as Chr-17 ≥2.2. CTCs were detected in 40 of 52 patients (76.9%) during the study period, in 32 of the 52 patients (61.5%) at baseline, and in 21 of 49 patients (42.9%) at 3-4 weeks. Polysomy 17 in CTCs was present in 10 of 52 patients (19.2%) during the study period, in 5 of 52 patients (9.6%) at baseline, and in 7 of 49 patients (14.3%) at 3-4 weeks. The individual patient counts of polysomy 17 in CTCs/total count of CTCs examined for polysomy 17 at 3-4 weeks were 1/1, 1/7, 1/7, 2/27, 2/30, 2/50, and 3/50. Six of the 7 patients with polysomy 17 in CTCs had HER2-negative primary tumors. None of the CTCs displaying polysomy 17 themselves had HER2 amplification by FISH. In summary, polysomy 17 in CTCs was observed in only a small population of patients with MBC. We should prospectively evaluate its prognostic value in both HER2-positive and -negative metastatic breast cancer.",

keywords = "Breast neoplasm, Circulating tumor cell, HER2, Metastasis, Polysomy",

author = "Naoki Hayashi and Seigo Nakamura and Hiroshi Yagata and Yuji Shimoda and Hidekazu Ota and Hortobagyi, {Gabriel N.} and Massimo Cristofanilli and Ueno, {Naoto T.}",

note = "Funding Information: The authors thank Bibari Nakamura, Keiko Shimizu, and all the staff from the Department of Breast Surgical Oncology, St. Luke{\textquoteright}s International Hospital, for help in collecting clinical data; Masayuki Shimada, Takeshi Watanabe, and Yuki Matsuo from SRL Inc. for tissue analysis; and Sunita Patterson from the Department of Scientific Publications, MD Anderson Cancer Center, for editorial review. This research is supported in part by the National Institutes of Health through MD Anderson{\textquoteright}s Cancer Center Support Grant, CA016672, and the Nellie B. Connally Breast Cancer Research Fund. Funding Information: G. N. Hortobagyi is a consultant to Merck, Novartis, and Sanofi-aventis, and received research funding from Novartis. Y. Shimada has employment with SRL Inc. The other authors have no conflict of interest.",

year = "2011",

month = oct,

doi = "10.1007/s10147-010-0173-3",

language = "English (US)",

volume = "16",

pages = "596--600",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer Japan",

number = "5",

}

TY - JOUR

T1 - Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer

T2 - A case series

AU - Hayashi, Naoki

AU - Nakamura, Seigo

AU - Yagata, Hiroshi

AU - Shimoda, Yuji

AU - Ota, Hidekazu

AU - Hortobagyi, Gabriel N.

AU - Cristofanilli, Massimo

AU - Ueno, Naoto T.

N1 - Funding Information: The authors thank Bibari Nakamura, Keiko Shimizu, and all the staff from the Department of Breast Surgical Oncology, St. Luke’s International Hospital, for help in collecting clinical data; Masayuki Shimada, Takeshi Watanabe, and Yuki Matsuo from SRL Inc. for tissue analysis; and Sunita Patterson from the Department of Scientific Publications, MD Anderson Cancer Center, for editorial review. This research is supported in part by the National Institutes of Health through MD Anderson’s Cancer Center Support Grant, CA016672, and the Nellie B. Connally Breast Cancer Research Fund. Funding Information: G. N. Hortobagyi is a consultant to Merck, Novartis, and Sanofi-aventis, and received research funding from Novartis. Y. Shimada has employment with SRL Inc. The other authors have no conflict of interest.

PY - 2011/10

Y1 - 2011/10

N2 - The human epidermal growth factor receptor 2 (HER2) gene is located on the long arm of chromosome 17 (Chr-17). While primary tumors with Chr-17 polysomy (polysomy 17) are histopathologically similar to HER2-negative tumors, the role of polysomy 17 in circulating tumor cells (CTCs) is still unknown. We report the detection rate of polysomy 17 in CTCs in patients with metastatic breast cancer (MBC). We determined the CTC count per 7.5 ml blood and polysomy 17 in CTCs at 3- to 4-week intervals up to 12 weeks in 52 patients. Polysomy was defined as Chr-17 ≥2.2. CTCs were detected in 40 of 52 patients (76.9%) during the study period, in 32 of the 52 patients (61.5%) at baseline, and in 21 of 49 patients (42.9%) at 3-4 weeks. Polysomy 17 in CTCs was present in 10 of 52 patients (19.2%) during the study period, in 5 of 52 patients (9.6%) at baseline, and in 7 of 49 patients (14.3%) at 3-4 weeks. The individual patient counts of polysomy 17 in CTCs/total count of CTCs examined for polysomy 17 at 3-4 weeks were 1/1, 1/7, 1/7, 2/27, 2/30, 2/50, and 3/50. Six of the 7 patients with polysomy 17 in CTCs had HER2-negative primary tumors. None of the CTCs displaying polysomy 17 themselves had HER2 amplification by FISH. In summary, polysomy 17 in CTCs was observed in only a small population of patients with MBC. We should prospectively evaluate its prognostic value in both HER2-positive and -negative metastatic breast cancer.

AB - The human epidermal growth factor receptor 2 (HER2) gene is located on the long arm of chromosome 17 (Chr-17). While primary tumors with Chr-17 polysomy (polysomy 17) are histopathologically similar to HER2-negative tumors, the role of polysomy 17 in circulating tumor cells (CTCs) is still unknown. We report the detection rate of polysomy 17 in CTCs in patients with metastatic breast cancer (MBC). We determined the CTC count per 7.5 ml blood and polysomy 17 in CTCs at 3- to 4-week intervals up to 12 weeks in 52 patients. Polysomy was defined as Chr-17 ≥2.2. CTCs were detected in 40 of 52 patients (76.9%) during the study period, in 32 of the 52 patients (61.5%) at baseline, and in 21 of 49 patients (42.9%) at 3-4 weeks. Polysomy 17 in CTCs was present in 10 of 52 patients (19.2%) during the study period, in 5 of 52 patients (9.6%) at baseline, and in 7 of 49 patients (14.3%) at 3-4 weeks. The individual patient counts of polysomy 17 in CTCs/total count of CTCs examined for polysomy 17 at 3-4 weeks were 1/1, 1/7, 1/7, 2/27, 2/30, 2/50, and 3/50. Six of the 7 patients with polysomy 17 in CTCs had HER2-negative primary tumors. None of the CTCs displaying polysomy 17 themselves had HER2 amplification by FISH. In summary, polysomy 17 in CTCs was observed in only a small population of patients with MBC. We should prospectively evaluate its prognostic value in both HER2-positive and -negative metastatic breast cancer.

KW - Breast neoplasm

KW - Circulating tumor cell

KW - HER2

KW - Metastasis

KW - Polysomy

UR - http://www.scopus.com/inward/record.url?scp=84857065490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857065490&partnerID=8YFLogxK

U2 - 10.1007/s10147-010-0173-3

DO - 10.1007/s10147-010-0173-3

M3 - Article

C2 - 21210173

AN - SCOPUS:84857065490

SN - 1341-9625

VL - 16

SP - 596

EP - 600

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

IS - 5

ER -

Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: A case series

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this